| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_de094784025e53546f898a3de5a5e393 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-7028
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96486
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-141
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2014-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e76fad7d624ef3e8e99eb28e1107cc06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae93a6b870d83304b387cc94d721957c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e16fb0e5a0df706921228b903cb313e2 |
| publicationDate |
2022-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2902420-T3 |
| titleOfInvention |
Compositions for the treatment of cancer expressing ADAM8 |
| abstract |
An ADAM8 ectodomain-binding antibody or antigen-binding fragment thereof for use in treating breast cancer or breast cancer-associated metastasis characterized in that the antibody or antigen-binding fragment thereof binds to the SEQ ID No 9 and that the antibody or antigen-binding fragment thereof inhibits the activity of the metalloproteinase domain and the disintegrin domain of ADAM8. |
| priorityDate |
2013-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |